Signaturefd LLC Purchases New Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC

Signaturefd LLC purchased a new stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 202 shares of the company’s stock, valued at approximately $49,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ONC. Perigon Wealth Management LLC purchased a new position in BeOne Medicines during the second quarter valued at $581,000. Public Employees Retirement System of Ohio purchased a new position in BeOne Medicines during the second quarter valued at $3,491,000. Avanza Fonder AB purchased a new position in BeOne Medicines during the second quarter valued at $199,000. Farther Finance Advisors LLC purchased a new position in BeOne Medicines during the second quarter valued at $39,000. Finally, Aaron Wealth Advisors LLC purchased a new position in BeOne Medicines during the second quarter valued at $200,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Insider Activity at BeOne Medicines

In other BeOne Medicines news, CEO John Oyler sold 27,803 shares of BeOne Medicines stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $325.71, for a total transaction of $9,055,715.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Lai Wang sold 5,000 shares of BeOne Medicines stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $350.06, for a total transaction of $1,750,300.00. The disclosure for this sale can be found here. Insiders sold 181,315 shares of company stock valued at $54,839,498 over the last ninety days. Corporate insiders own 6.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Guggenheim increased their price objective on shares of BeOne Medicines from $350.00 to $365.00 and gave the company a “buy” rating in a report on Thursday, August 7th. Royal Bank Of Canada increased their price objective on shares of BeOne Medicines from $349.00 to $364.00 and gave the company an “outperform” rating in a report on Thursday, August 7th. Zacks Research raised shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 18th. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Friday. Finally, Barclays began coverage on shares of BeOne Medicines in a report on Thursday, September 18th. They set an “overweight” rating and a $385.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $336.30.

BeOne Medicines Price Performance

Shares of ONC stock opened at $344.53 on Tuesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.95 and a quick ratio of 1.72. The firm’s 50-day moving average is $319.57 and its two-hundred day moving average is $274.54. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $170.99 and a 12 month high of $355.30. The company has a market capitalization of $37.76 billion, a PE ratio of -199.15 and a beta of 0.31.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.36. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.24 billion. Analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 earnings per share for the current year.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.